Meeting
2020 ASCO Virtual Scientific Program
Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.
Authors
Tina Cascone
The University of Texas MD Anderson Cancer Center, Houston, TX
Tina Cascone , Mariano Provencio , Boris Sepesi , Shun Lu , Nivedita Aanur , Sunney Li , Jonathan Spicer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04025879
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS9076)
DOI
10.1200/JCO.2020.38.15_suppl.TPS9076
Abstract #
TPS9076
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageⅠB-ⅢA non-small cell lung cancer.
First Author: Xue-ning Yang
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2017 ASCO Annual Meeting
Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.
First Author: Patrick M. Forde
Poster
2014 ASCO Quality Care Symposium
Adjuvant chemotherapy selection for stage I NSCLC 2011 through 2014 in the southeastern United States..
First Author: Avinash Mamgain